In this episode we take a closer look at the data collection for respiratory viruses and why we should take this more seriously than just a cough or a sneeze.
During the 2023 West Nile virus transmission season, and as of 4 January 2024, 709 locally acquired human cases of West Nile virus infection, including 67 deaths, were reported by nine European Union countries.
Several viral and bacterial respiratory pathogens are expected to continue co-circulating at variable levels during the coming months, and contribute to increased morbidity and mortality during this period. This is typical of every winter season.
Campylobacteriosis and salmonellosis were the most frequently reported zoonotic diseases in humans in the EU in 2022. For West Nile virus, an increase of the number of infections was observed.
ECDC and World Health Organization (WHO) Regional Office for Europe have jointly developed the European Respiratory Virus Surveillance Summary (ERVISS), an interactive surveillance data dashboard for influenza, respiratory syncytial virus (RSV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that also features a weekly epidemiological summary.
As autumn moves to winter, the WHO/Europe, EC and ECDC are issuing a clear, urgent message: people who remain unprotected against both COVID-19 and seasonal influenza – especially the most vulnerable and at-risk – should take up any offer for vaccination to prevent or mitigate the impact of these co-circulating respiratory infections.
As of 30 June 2023, European Union, European Economic Area and EU-neighbouring countries have reported 1 340 locally acquired human cases of West Nile virus infection, including 104 deaths, in 2022.
The mosquito species Aedes albopictus, a known vector of chikungunya and dengue viruses, is establishing itself further northwards and westwards in Europe, according to the latest data.